Cerapedics announces closing of venture debt loan from GE Capital
Cerapedics today announced closing of a $9 million venture debt financing from GE Capital, Healthcare Financial Services.
Find out moreCerapedics announces positive results from IDE clinical trial
Results provide significant support to advance i-FACTOR™ Peptide Enhanced Bone Graft for FDA regulatory review.
Find out moreCerapedics to present preliminary outcomes data From i-FACTOR Bone Graft Study at Canaccord Genuity Musculoskeletal Conference
Cerapedics today that preliminary outcomes data from the company's FDA Investigational Device Exemption (IDE) clinical trial for i-FACTOR Peptide Enhanced Bone Graft will be presented at the Canaccord Genuity Muscul…
Find out more
Welcome to Cerapedics
Choose your region
